Blue Matter Launches Behavioral Science Center of Excellence to Decode Healthcare Decision-Making
Blue Matter has announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the company’s Blue Matter Insights primary market research team designed to provide deeper insight into the factors that influence healthcare decision-making.
The new Center of Excellence brings behavioral science into the strategic research process to help biopharmaceutical companies better understand the “why” behind decisions made by healthcare professionals, patients, care partners and other stakeholders across the healthcare ecosystem.
As the biopharmaceutical industry becomes increasingly complex, understanding stakeholder behavior is becoming an important component of commercial strategy, product development and market planning. While conventional market research can provide valuable information about what stakeholders say, Blue Matter says behavioral science can help uncover the less visible factors that influence what people ultimately do.
These factors can include unconscious motivations, cognitive biases, emotions, social influences, environmental conditions and the context in which decisions are made. By examining these elements alongside traditional research findings, the BeSci CoE aims to provide clients with a more comprehensive understanding of healthcare decision-making.
Addressing the Gap Between What Stakeholders Say and What They Do
Healthcare professionals and patients frequently make decisions in environments where multiple factors interact. A physician may identify clinical efficacy as a major consideration when discussing treatment selection, for example, while actual prescribing behavior may also be influenced by patient characteristics, clinical experience, workflow considerations, familiarity with a therapy, access restrictions, institutional protocols and other contextual factors.
This creates what Blue Matter describes as a “say-do” gap—the difference between what stakeholders report as influencing their decisions and the factors that ultimately shape their behavior.
Traditional surveys and interviews can identify stated preferences and attitudes, but they may not always reveal the underlying mechanisms responsible for behavior. Behavioral science offers a framework for investigating those mechanisms and understanding why actual behavior may differ from stated intentions.
“You don’t need a survey to tell you that physicians see efficacy as the most important treatment decision driver,” said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. “What our clients come to us for is an understanding of why real-world prescribing often diverges from this perspective. That’s where behavioral science comes in: it gives us the best way to bridge this ‘say-do’ gap.”
The BeSci CoE is intended to address this challenge by incorporating behavioral science into research programs rather than treating it as a separate or standalone exercise.
Supporting Strategic Decisions Across the Biopharma Lifecycle
Blue Matter said the Center of Excellence will support a broad range of medical, market access, new product planning and commercial functions. Its services are intended for both established biopharmaceutical companies and emerging innovators navigating critical decisions throughout a product’s development and commercialization lifecycle.
Behavioral science can be particularly relevant at points where companies need to understand how different stakeholders may respond to a new product, message, treatment option or change in the healthcare environment.
For example, behavioral insights can contribute to positioning strategy by helping companies determine which messages are most likely to influence stakeholder perceptions and actions. During product launch planning, these insights can help identify behavioral barriers and opportunities that may affect adoption. Behavioral science can also support lifecycle decisions, where companies need to anticipate how changing evidence, competitive dynamics and stakeholder expectations could influence future behavior.
The BeSci CoE’s work includes applying behavioral science frameworks across qualitative, quantitative and mixed-method research. This allows researchers to examine stakeholder behavior using multiple approaches rather than relying on a single research methodology.
The Center also focuses on translating behavioral findings into strategic and tactical recommendations. Rather than stopping at the identification of behavioral drivers, the goal is to connect those insights with practical decisions that clients can use in market strategy, planning and execution.
Another area of focus is the identification of early signals that could indicate how behavior and market dynamics may change over time. In fast-moving healthcare markets, recognizing emerging changes in stakeholder attitudes and behaviors can be important for companies preparing for shifts in treatment patterns, market access conditions or competitive environments.
Integrating Behavioral Science With Market Research and Analytics
Blue Matter said behavioral science has already been incorporated into a number of its existing methodologies. The establishment of the BeSci CoE formalizes that expertise and creates a dedicated structure for applying behavioral science more consistently across the company’s capabilities.
The Center is integrated with Blue Matter’s primary market research and data analytics capabilities. This combination is intended to connect qualitative and quantitative research with broader analytical approaches, enabling clients to examine both what stakeholders report and the behavioral factors that may influence their actions.
By bringing behavioral science together with primary market research, Blue Matter can investigate decision-making from multiple perspectives. Qualitative research may help explore motivations, perceptions and contextual factors, while quantitative methods can help measure patterns across larger stakeholder populations. Data analytics can then provide additional insight into relationships and trends within the available evidence.
The integrated approach is particularly relevant in biopharmaceutical markets, where decisions are rarely driven by a single factor. Physicians, patients, care partners and other stakeholders operate within complex systems that combine clinical, economic, behavioral and environmental considerations.
Blue Matter’s new Center of Excellence is designed to help clients interpret those interactions and translate them into actionable insights.
Building on Academic and Industry Expertise
The BeSci CoE brings together team members with academic backgrounds in behavioral science and related disciplines, along with practical experience working with biopharmaceutical companies.
According to Blue Matter, the team combines academic credentials with years of applied experience in the biopharmaceutical sector. This combination is intended to ensure that behavioral science frameworks are applied in ways that are relevant to real-world commercial and healthcare challenges.
The company also plans to continue sharing findings and evidence generated through its behavioral science work with the broader industry and scientific community.
These efforts include peer-reviewed manuscripts, white papers, conference presentations and speaker events. By sharing research externally, Blue Matter aims to contribute to the growing application of behavioral science in healthcare and biopharmaceutical decision-making.
The company’s emphasis on evidence-based behavioral research also reflects the broader need for healthcare insights that move beyond descriptive findings. Understanding that a particular factor is associated with a decision can be useful, but understanding the mechanism through which that factor influences behavior can provide additional strategic context.
Behavioral Science as a Core Research Capability
D’Arcy King, Ph.D., Partner and Head of Primary Market Research at Blue Matter, said behavioral science is already embedded in the company’s approach to understanding healthcare markets.
“Behavioral science isn’t a bolt-on technique for us. It is central to how we understand decision-making in complex, fast-moving markets,” King said.
She added that formalizing this expertise through a Center of Excellence establishes a dedicated structure for delivering behavioral-science-driven insights to clients.
“By formalizing this expertise in a Center of Excellence, we are setting a higher bar for what behavioral-science-driven insights should deliver: clarity and confidence in stakeholder decision-making,” she said.
The launch reflects the growing importance of understanding behavior alongside attitudes and stated preferences in biopharmaceutical market research. As healthcare stakeholders face increasingly complex treatment choices, access considerations and information environments, companies require research approaches capable of examining not only what people say, but also the factors that influence their decisions in real-world settings.
Through the Behavioral Science Center of Excellence, Blue Matter is expanding its ability to apply behavioral frameworks across primary market research, analytics and strategic consulting. The capability is positioned to support pharmaceutical and biotechnology companies as they address decisions ranging from early product planning and market positioning to launch preparation and long-term lifecycle strategy.
Ultimately, the BeSci CoE is intended to provide a deeper perspective on healthcare decision-making by connecting observed and reported behaviors with the psychological, contextual and environmental factors that shape them. For biopharmaceutical organizations operating in rapidly evolving markets, this approach can provide additional evidence for understanding stakeholder behavior and informing decisions throughout the product lifecycle.
About Blue Matter
Blue Matter (www.bluematterconsulting.com) is a global commercialization partner serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves a broad spectrum of biopharmaceutical organizations, from top-20 global companies to emerging biotech firms. Blue Matter helps clients maximize value at the product, portfolio, and organization levels by providing market insights, strategic and operational consulting, and communications services.